The screening and workforce reentry solution includes clinically overseen COVID-19 diagnostic and antibody testing; a population analytics, engagement, and monitoring technology platform; and a comprehensive return-to-work action plan. [05-June-2020] ATLANTA , June 5, 2020 /PRNewswire/ -- BioIQ , a healthcare engagement and clinical adherence technology platform comp
| ATLANTA, June 5, 2020 /PRNewswire/ -- BioIQ, a healthcare engagement and clinical adherence technology platform company, has partnered with Cresa and Ogletree Deakins to help employers navigate the many practical and legal issues to consider when crafting a workplace COVID-19 testing and return-to-work strategy. The BioIQ return-to-work ecosystem is designed to move employers up the learning curve quickly and expedite efforts to reopen the US economy.
BioIQ and Ogletree Deakins, one of the largest labor and employment law firms representing management, have developed an extensive Testing and Screening Guide. The guide advises employers on the different types of health screenings that are possible, legal obligations related to health screenings, whether screening time is compensable, related privacy concerns, needed accommodations, and jurisdiction-specific compliance requirements. “As employers plan to return employees to the workplace, many are adopting some form of testing or health screen, whether for employees, visitors, or both,” said Ogletree Deakins shareholder Ron Chapman, Jr. “The Guide anticipates the many legal pitfalls in these scenarios and provides specific recommendations on how to navigate them successfully.”
Cresa, the world’s largest commercial real estate advisory firm that exclusively represents occupiers, will offer employers guidance on workspace considerations as part of the return-to-office strategy. Their Workspace Planning, Design, and Support team helps develop a near-term approach for reentry by creating plans that ensure social distancing and productivity. “As businesses pivot to meet current guidelines, re-examining workspaces in a way that considers employee safety, remote workforce implications, and employee productivity will be critical,” said Gillian Baikie, Planning and Design Director, Cresa Workspace Planning, Design, and Support. Cresa Senior Vice President Brooks Morris also addresses the top clinical protocols businesses need to consider in order to ensure a successful return-to-office strategy. Designed to offer employers guidance on how to confidently and expeditiously bring workers back in, the BioIQ COVID-19 testing and return-to-work ecosystem includes:
The BioIQ back-to-work COVID-19 testing solution enables employers to implement a thoughtful testing strategy that is mindful of critical roles and high-risk employees; a long-term containment and assessment strategy; and protocol for managing impacted and returning employees. The solution ecosystem offers step-by-step guidance on measures businesses can initiate to prepare for workforce reentry as restrictions are raised. “With companies across the country starting to plan their return to the office, now is the time to assess your return-to-work procedures and policies,” said BioIQ CEO Justin Bellante. “Our partnership with Cresa and Ogletree Deakins further supports our goal to help employers intelligently and safely bring employees back to the workplace and to help the US economy reopen.” The companies collectively seek to allay employers’ concerns related to testing execution and return-to-work considerations and liabilities. “Employers face tough decisions in safely returning to work. Not only do we want to provide the platform and testing to make that a reality, we also want to provide insight and guidance to give them peace of mind and ensure they are using best practices from national experts in key areas,” said Bellante. At 12pm ET, on Wednesday, June 10, join Ogletree Deakins, Cresa, and BioIQ for a discussion on the top issues workplaces need to address to re-open. Register for the Sustainable Return to Work Strategies webinar series here. To learn more about BioIQ’s COVID-19 testing solutions, call 888-818-1594 or visit https://www.bioiq.com/covid-19-solution/. About BioIQ With more than a decade of healthcare industry experience and a first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit www.bioiq.com. About Cresa About Ogletree Deakins Contact:
SOURCE BioIQ |
View original content to download multimedia:
